Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Gastroprokinetic agent Stories

2012-06-06 06:26:33

BOSTON, June 6, 2012 /PRNewswire/ -- Rhythm announced today the initiation of a Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of gastroparesis in patients with Type I and Type II diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastric motility. "We are excited about the clinical profile of RM-131 as we bring it forward into Phase 2 development," said Liz Stoner, MD, Chief Development Officer of Rhythm. "Extensive...

2012-05-22 06:25:26

BOSTON, May 22, 2012 /PRNewswire/ -- Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis. The trial demonstrated that RM-131 greatly accelerates gastric emptying in patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2012 conference in San Diego. The Phase 1b clinical trial was a randomized, double-blind, placebo-controlled, single-dose crossover...

2012-04-30 15:31:02

The common antibiotic, amoxicillin-clavulanate, may improve small bowel function in children experiencing motility disturbances, according to a study appearing in the June print edition of the Journal of Pediatric Gastroenterology and Nutrition from Nationwide Children´s Hospital. Amoxicillan-clavulanate, also known as Augmentin, is most commonly prescribed to treat or prevent infections caused by bacteria. However, it has also been reported to increase small bowel motility in healthy...

2011-08-08 12:24:53

Modifying stomach acid levels may not be enough to treat symptoms in neonates suspected of having gastroesophageal reflux disease. According to a study from Nationwide Children's Hospital, this is the first study to classify reflux and its associated symptoms in neonates based on how and what is refluxed. Gastroesophageal reflux disease (GERD) is a frequent consideration in infants at risk of the life-threatening events chronic lung disease and dysphagia. Yet, the definition of GERD in...

2011-05-09 07:00:00

BOSTON, May 9, 2011 /PRNewswire/ -- Rhythm announced today results demonstrating that RM-131, the company's novel ghrelin agonist, was highly effective in restoring normal gastric function in animal models of delayed gastric emptying owing to a direct prokinetic effect. The results were the subject of an oral presentation by Lee M. Kaplan, MD, PhD (Massachusetts General Hospital, Harvard Medical School) titled "RM-131: A Potent Gastroprokinetic Agent" at the Digestive Disease Week 2011...

2008-12-29 17:05:58

Some in South Korea experience chronic gastrointestinal symptoms fairly frequently, researchers said. Researchers led by Dr. Myung-Gyu Choi of the Kangnam St. Mary's Hospital, The Catholic University of Korea, in Seoul performed a cross-sectional survey on randomly selected residents in Asan-Si, Korea. The authors assessed chronic gastrointestinal symptoms, using a Rome II based questionnaire. Of the 1,807 eligible subjects, 1,417 were surveyed, with a face-to-face interview. The prevalence...

2008-10-28 18:00:28

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Oppenheimer & Co. 19th Annual Health Care Conference in New York, NY. A live webcast of the presentation scheduled for Tuesday, November 4 at 2:40 p.m. Eastern Time may be accessed at the ARYx website http://www.aryx.com. The presentation will be archived for 90 days. About ARYx Therapeutics, Inc. ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally...

2008-07-02 18:00:33

ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced that Procter & Gamble Pharmaceuticals, Inc. (P&G) has utilized a one-time thirty day cancellation option linked to the completion of a Thorough QT (TQT) study to end the collaboration agreement between the companies covering the late-stage development and commercialization of ATI-7505, a prokinetic agent in Phase 2 clinical trials for chronic constipation and functional dyspepsia. The results of the...

2008-06-23 06:00:06

Tranzyme Pharma announces the successful results from a "Thorough QT/QTc" study of the company's lead product TZP-101, an intravenous gastrointestinal prokinetic agent currently in two Phase IIb trials for the treatment of postoperative ileus (POI) and severe gastroparesis. The study, required by the US Food and Drug Administration (FDA) for all new chemical entities, was conducted to evaluate the cardiac safety of TZP-101, with a focus on cardiac repolarization as measured by the...

2008-06-17 06:00:07

Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development. It is a potent prokinetic agent initially being developed for the treatment of mild-to-moderate gastroparesis. The Phase I study showed that TZP-102 has excellent oral bioavailability in man and is safe and...